Afficher la couverture 'Shiga Toxin-Associated Hemolytic Uremic Syndrome in Adults, France, 2009-2017 | Travert, Benoit' en grand format
/5

0 avis

Shiga Toxin-Associated Hemolytic Uremic Syndrome in Adults, France, 2009-2017

Archive ouverte

Travert, Benoit | Dossier, Antoine | Jamme, Matthieu | Cointe, Aurelie | Delmas, Yahsou | Malot, Sandrine | Wynckel, Alain | Seguin, Amelie | Presne, Claire | Hie, Miguel | Benhamou, Ygal | Ribes, David | Choukroun, Gabriel | Grange, Steven | Hertig, Alexandre | Cornec-Le Gall, Emilie | Galicier, Lionel | Daugas, Eric | Bouadma, Lila | Weill, Francois-Xavier | Azoulay, Elie | Fakhouri, Fadi | Veyradier, Agnes | Bonacorsi, Stephane | Hogan, Julien | Fremeaux-Bacchi, Veronique | Rondeau, Eric | Mariani-Kurkdjian, Patricia | Coppo, Paul

Edité par CCSD ; Centers for Disease Control and Prevention -

International audience. We conducted a retrospective study on hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli (STEC) in 96 adults enrolled in the cohort of the National Reference Center for Thrombotic Microangiopathies network in France during 2009-2017. Most infections were caused by STEC strains not belonging to the O157 or O104 serogroups. Thirty (31.3%) patients had multiple risk factors for thrombotic microangiopathy. In total, 61 (63.5%) patients required dialysis, 50 (52.1%) had a serious neurologic complication, 34 (35.4%) required mechanical ventilation, and 19 (19.8%) died during hospitalization. We used multivariate analysis to determine that the greatest risk factors for death were underlying immunodeficiency (hazard ratio 3.54) and severe neurologic events (hazard ratio 3.40). According to multivariate analysis and propensity score-matching, eculizuma b treatment was not associated with survival. We found that underlying conditions, especially immunodeficiency, are strongly associated with decreased survival in adults who have hemolytic uremic syndrome caused by STEC.

Suggestions

Du même auteur

Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience.

Archive ouverte | Benhamou, Ygal | CCSD

International audience. Background. Acquired thrombotic thrombocytopenic purpura is still associated with a 10-20% death rate. So far, early prognostic factors of death could not be clearly identified. To identify p...

A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP

Archive ouverte | Coppo, Paul | CCSD

International audience. The anti–von Willebrand factor nanobody caplacizumab was licensed for adults with immune-mediated thrombotic thrombocytopenic purpura (iTTP) based on prospective controlled trials. However, f...

High prevalence of infectious events in thrombotic thrombocytopenic purpura and genetic relationship with toll-like receptor 9 polymorphisms: experience of the French Thrombotic Microangiopathies Reference Center

Archive ouverte | Morgand, Marjolaine | CCSD

National audience. BACKGROUND: Infectious events have been reported as major environmental triggers of thrombotic thrombocytopenic purpura (TTP). We detail here the potential association between infections and TTP. ...

Chargement des enrichissements...